Patient characteristics
| Characteristic . | Value . |
|---|---|
| Patient age, median (IQR), y | 63 (55-67) |
| Male sex, no. (%) | 49 (64) |
| Race/ethnicity, no. (%) | |
| White | 65 (86) |
| Hispanic | 7 (9) |
| African American | 3 (4) |
| Asian | 3 (4) |
| Native Alaskan or Hawaiian | 3 (4) |
| Not reported | 2 (3) |
| Donor age, median (IQR), y | 29 (25-41) |
| Unrelated donor, no. (%) | 70 (92) |
| HLA class I mismatch, no. (%)* | 51 (67) |
| HLA class II mismatch, no. (%)† | 25 (33) |
| HLA mismatch vector, no. (%) | |
| Both host-versus-graft and GVHD | 68 (89) |
| Host-versus-graft | 3 (4) |
| GVHD | 5 (7) |
| Sex of patient/donor, no. (%) | |
| Male/female | 11 (14) |
| Other combinations | 65 (86) |
| CMV serostatus of patient/donor, no. (%) | |
| Negative/negative | 21 (28) |
| Negative/positive | 7 (9) |
| Positive/negative | 23 (31) |
| Positive/positive | 24 (32) |
| Prior high-dose HCT, no. (%) | |
| Autologous | 18 (23) |
| Allogeneic | 2 (3) |
| Diagnoses, no. (%) | |
| Acute myeloid leukemia | 23 (30) |
| MDS/MPD | 20 (27) |
| Chronic myeloid leukemia | 1 (1) |
| Acute lymphoblastic leukemia | 3 (4) |
| Non-Hodgkin lymphoma | 12 (16) |
| Chronic lymphocytic leukemia | 10 (13) |
| Hodgkin lymphoma | 2 (3) |
| Multiple myeloma | 5 (7) |
| Relapse risk,8 no. (%) | |
| Low | 23 (30) |
| Standard | 35 (46) |
| High | 18 (24) |
| Disease risk index,9 no. (%) | |
| Low | 8 (11) |
| Intermediate | 50 (66) |
| High | 18 (24) |
| HCT comorbidity index, no. (%) | |
| 0 | 10 (13) |
| 1, 2 | 22 (29) |
| 3+ | 44 (58) |
| TBI, no. (%) | |
| 2 Gy | 30 (39) |
| 3 Gy | 46 (61) |
| CD34+ cells × 106/ kg, median (IQR) | 8.3 (6.4-10.1) |
| CD3+ cells × 108/ kg, median (IQR) | 2.7 (2.2-3.6) |
| Karnofsky performance status, no. (%) | |
| 100 | 12 (16) |
| 90 | 36 (47) |
| 80-85 | 24 (32) |
| <80 | 4 (5) |
| Characteristic . | Value . |
|---|---|
| Patient age, median (IQR), y | 63 (55-67) |
| Male sex, no. (%) | 49 (64) |
| Race/ethnicity, no. (%) | |
| White | 65 (86) |
| Hispanic | 7 (9) |
| African American | 3 (4) |
| Asian | 3 (4) |
| Native Alaskan or Hawaiian | 3 (4) |
| Not reported | 2 (3) |
| Donor age, median (IQR), y | 29 (25-41) |
| Unrelated donor, no. (%) | 70 (92) |
| HLA class I mismatch, no. (%)* | 51 (67) |
| HLA class II mismatch, no. (%)† | 25 (33) |
| HLA mismatch vector, no. (%) | |
| Both host-versus-graft and GVHD | 68 (89) |
| Host-versus-graft | 3 (4) |
| GVHD | 5 (7) |
| Sex of patient/donor, no. (%) | |
| Male/female | 11 (14) |
| Other combinations | 65 (86) |
| CMV serostatus of patient/donor, no. (%) | |
| Negative/negative | 21 (28) |
| Negative/positive | 7 (9) |
| Positive/negative | 23 (31) |
| Positive/positive | 24 (32) |
| Prior high-dose HCT, no. (%) | |
| Autologous | 18 (23) |
| Allogeneic | 2 (3) |
| Diagnoses, no. (%) | |
| Acute myeloid leukemia | 23 (30) |
| MDS/MPD | 20 (27) |
| Chronic myeloid leukemia | 1 (1) |
| Acute lymphoblastic leukemia | 3 (4) |
| Non-Hodgkin lymphoma | 12 (16) |
| Chronic lymphocytic leukemia | 10 (13) |
| Hodgkin lymphoma | 2 (3) |
| Multiple myeloma | 5 (7) |
| Relapse risk,8 no. (%) | |
| Low | 23 (30) |
| Standard | 35 (46) |
| High | 18 (24) |
| Disease risk index,9 no. (%) | |
| Low | 8 (11) |
| Intermediate | 50 (66) |
| High | 18 (24) |
| HCT comorbidity index, no. (%) | |
| 0 | 10 (13) |
| 1, 2 | 22 (29) |
| 3+ | 44 (58) |
| TBI, no. (%) | |
| 2 Gy | 30 (39) |
| 3 Gy | 46 (61) |
| CD34+ cells × 106/ kg, median (IQR) | 8.3 (6.4-10.1) |
| CD3+ cells × 108/ kg, median (IQR) | 2.7 (2.2-3.6) |
| Karnofsky performance status, no. (%) | |
| 100 | 12 (16) |
| 90 | 36 (47) |
| 80-85 | 24 (32) |
| <80 | 4 (5) |
CMV, cytomegalovirus; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease.
Single antigen mismatched: HLA-A, n = 33 (43%); HLA-B, n = 11 (14%); and HLA-C, n = 6 (8%). One patient (1%) was mismatched for one HLA-A antigen and one HLA-B allele.
Single antigen mismatches: HLA-DQB1, n = 8 (11%); and HLA-DRB1, n = 7 (9%). Single allele mismatches: HLA-DQB1, n = 4 (5%); and HLA-DRB1, n = 5 (7%). One (1%) patient was mismatched for a single allele on both HLA-DQB1 and HLA-DRB1.